The FBXW7-binding sites on FAM83D are potential targets for cancer therapy
Abstract Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding sites on FAM83D led to that FAM83D lost its capability to promote the ubiquitination and proteasomal degradation of FBXW7; cell proliferation, migration, and invasion in vitro; and tumor growth and metastasis in vivo, indicating that the FBXW7-binding sites on FAM83D are essential for its oncogenic functions. A meta-evaluation of FAM83D revealed that the prognostic impact of FAM83D was independent on molecular subtypes. The higher expression of FAM83D has poorer prognosis. Moreover, high expression of FAM83D confers resistance to chemotherapy in BCs, which is experimentally validated in vitro. We conclude that identification of FBXW7-binding sites on FAM83D not only reveals the importance for FAM83D oncogenic function, but also provides valuable insights for drug target..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Breast cancer research - 26(2024), 1 vom: 07. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Xiaoyu [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s13058-024-01795-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055059937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055059937 | ||
| 003 | DE-627 | ||
| 005 | 20240308064708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13058-024-01795-9 |2 doi | |
| 035 | |a (DE-627)SPR055059937 | ||
| 035 | |a (SPR)s13058-024-01795-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Xiaoyu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The FBXW7-binding sites on FAM83D are potential targets for cancer therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding sites on FAM83D led to that FAM83D lost its capability to promote the ubiquitination and proteasomal degradation of FBXW7; cell proliferation, migration, and invasion in vitro; and tumor growth and metastasis in vivo, indicating that the FBXW7-binding sites on FAM83D are essential for its oncogenic functions. A meta-evaluation of FAM83D revealed that the prognostic impact of FAM83D was independent on molecular subtypes. The higher expression of FAM83D has poorer prognosis. Moreover, high expression of FAM83D confers resistance to chemotherapy in BCs, which is experimentally validated in vitro. We conclude that identification of FBXW7-binding sites on FAM83D not only reveals the importance for FAM83D oncogenic function, but also provides valuable insights for drug target. | ||
| 650 | 4 | |a FBXW7 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FAM83D |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ubiquitination and degradation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Breast cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metastasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wang, Yuli |4 aut | |
| 700 | 1 | |a Guo, Lulu |4 aut | |
| 700 | 1 | |a Wang, Yige |4 aut | |
| 700 | 1 | |a Miao, Tianshu |4 aut | |
| 700 | 1 | |a Ma, Lijuan |4 aut | |
| 700 | 1 | |a Wei, Qin |4 aut | |
| 700 | 1 | |a Lin, Xiaoyan |4 aut | |
| 700 | 1 | |a Mao, Jian-Hua |4 aut | |
| 700 | 1 | |a Zhang, Pengju |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research |d London : BioMed Central, 1999 |g 26(2024), 1 vom: 07. März |w (DE-627)SPR029910110 |w (DE-600)2041618-0 |x 1465-542X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:1 |g day:07 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13058-024-01795-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 1 |b 07 |c 03 | ||